LumiraDx Limited: LumiraDx Announces FDA EUA Submission for

- Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral

Related Keywords

United States , United Kingdom , London , City Of , Ron Zwanziger , Colleen Mcmillen , Exchange Commission , Department Of Health , Human Services , National Institutes Of Health , Drug Administration , National Institute Of Biomedical Imaging , Lumiradx Platform , Emergency Use Authorization , Lumiradx Point , Care Platform , Lumiradx Chief Executive Officer , National Institute , Biomedical Imaging , National Institutes , Securities Litigation Reform Act , Proxy Statement , Lumiradx , Imited , Nnounces , Submission , Cars , Rapid , Ntigen , Pest ,